Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)GORDON, Leo I.Seminars in oncology. 2003, Vol 30, Num 6, pp 23-28, issn 0093-7754, 6 p., SUP17Article

Diagnostic and therapeutic advances in hematologic malignanciesTALLMAN, Martin S; GORDON, Leo I.Cancer treatment and research. 1999, Vol 99, issn 0927-3042, 384 p.Serial Issue

Transformation of follicular lymphoma to acute lymphoblastic leukemiaXIAOPING SUN; GORDON, Leo I; PETERSON, Loann C et al.Archives of pathology & laboratory medicine (1976). 2002, Vol 126, Num 8, pp 997-998, issn 0363-0153Article

Thrombotic microangiopathy in the cancer patientKWAAN, Hau C; GORDON, Leo I.Acta haematologica. 2001, Vol 106, Num 1-2, pp 52-56, issn 0001-5792Article

Bone marrow and stem cell transplantation for multiple myelomaVESOLE, D. H.Cancer treatment and research. 1999, Vol 99, pp 171-194, issn 0927-3042Article

Novel treatment approaches for cutaneous T-cell lymphomaFOSS, F. M; KUZEL, T. M.Cancer treatment and research. 1999, Vol 99, pp 227-240, issn 0927-3042Article

Recent advances in the biology and management of acute lymphoblastic leukemia in adultsO'CONNOR, O. A; WEISS, M.Cancer treatment and research. 1999, Vol 99, pp 307-333, issn 0927-3042Article

New classifications for non-Hodgkin's lymphomaFINN, W. G; KROFT, S. H.Cancer treatment and research. 1999, Vol 99, pp 1-26, issn 0927-3042Article

Current approaches to acute promyelocytic leukemiaFRANKEL, S. R; POWELL, B. L.Cancer treatment and research. 1999, Vol 99, pp 125-153, issn 0927-3042Article

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2ADARGART, Jamie L; FISH, Kamonwan; GORDON, Leo I et al.Antiviral research. 2012, Vol 95, Num 1, pp 49-56, issn 0166-3542, 8 p.Article

Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignanciesBO SHI; HSU, Hsin-Ling; EVENS, Andy M et al.Blood. 2003, Vol 102, Num 1, pp 297-302, issn 0006-4971, 6 p.Article

The molecular biology of acute promyelocytic leukemiaSLACK, J. L; GALLAGHER, R. E.Cancer treatment and research. 1999, Vol 99, pp 75-124, issn 0927-3042Article

AIDS-associated lymphomaVOLM, M. D; VON ROENN, J. H.Cancer treatment and research. 1999, Vol 99, pp 241-266, issn 0927-3042Article

Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: Enhancement of apoptosis by manipulation of cellular redox stateGARTENHAUS, Ronald B; PRACHAND, Sheila N; PANIAQUA, Mary et al.Clinical cancer research. 2002, Vol 8, Num 2, pp 566-572, issn 1078-0432Article

Therapy of diffuse aggressive lymphomasKOC, Y; SCHENKEIN, D. P.Cancer treatment and research. 1999, Vol 99, pp 47-73, issn 0927-3042Article

Prognosis in multiple myelomaFONSECA, R; GREIPP, P. R.Cancer treatment and research. 1999, Vol 99, pp 155-170, issn 0927-3042Article

Hematopoietic growth factors and acute leukemiaROWE, J. M; LIESVELD, J. L.Cancer treatment and research. 1999, Vol 99, pp 195-226, issn 0927-3042Article

Novel biologic approaches to hematologic malignanciesDUTCHER, J. P; WIERNIK, P. H.Cancer treatment and research. 1999, Vol 99, pp 275-306, issn 0927-3042Article

Motexafin Gadolinium Enhances p53-Mdm2 Interactions, Reducing p53 and Downstream Targets in Lymphoma Cell LinesSINGH, Amareshwar T. K; EVENS, Andrew M; PRACHAND, Sheila N et al.Anticancer research. 2010, Vol 30, Num 4, pp 1131-1136, issn 0250-7005, 6 p.Article

Advances in the therapy of the myelodysplastic syndromesKOUIDES, P. A; BENNETT, J. M.Cancer treatment and research. 1999, Vol 99, pp 335-362, issn 0927-3042Article

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraEVENS, Andrew M; DAVID, Kevin A; CHADBURN, Amy et al.Journal of clinical oncology. 2010, Vol 28, Num 6, pp 1038-1046, issn 0732-183X, 9 p.Conference Paper

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [⁹⁰Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I TrialEVENS, Andrew M; SPIES, William G; NAUMOVSKI, Louie et al.Clinical cancer research (Print). 2009, Vol 15, Num 20, pp 6462-6471, issn 1078-0432, 10 p.Article

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant : long-term follow-up in newly diagnosed mantle cell lymphomaEVENS, Andrew M; WINTER, Jane N; MEHTA, Jayesh et al.British journal of haematology. 2008, Vol 140, Num 4, pp 385-393, issn 0007-1048, 9 p.Article

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20⁺ B-cell lymphoma: long-term follow-up of a phase 1/2 studyGORDON, Leo I; MOLINA, Arturo; WITZIG, Thomas et al.Blood. 2004, Vol 103, Num 12, pp 4429-4431, issn 0006-4971, 3 p.Article

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II studyEVENS, Andrew M; SMITH, Mitchell R; LOSSOS, Izidore S et al.British journal of haematology. 2014, Vol 166, Num 4, pp 514-520, issn 0007-1048, 7 p.Article